MedTrace Logo

Liposomal Amikacin Inhalation in M.Abscessus Patients

NCT04163601 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2020-02-12

No results posted yet for this study

Summary

Mycobacterium abscessus is one of the many species of non-tuberculous mycobacteria. M. abscessus infections are known to be common in patients with cystic fibrosis (CF). Mycobacterium abscessus yields poor cure rates. Liposomal amikacin inhalation (LAI) might be a good alternative for intravenous treatment as the first results with mycobacterium avium treatment yield good results.

The objective of this study is to summarize the clinical data of patients with M.abscessus treated with LAI on compassionate use basis to assess treatment outcomes

Conditions

  • M.Abscessus Pulmonary Disease

Sponsors & Collaborators

  • European network (http://www.ntm-net.org/index.php/ntm-net)

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Raphael CHIRON, PU-PH · University Hospitals of Montpellier

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-30
Primary Completion
2020-12-01
Completion
2024-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04163601 on ClinicalTrials.gov